HLVX Financials: Hillevax Inc AI Analysis

Home

Stock

HLVX

Financials

HLVX Financial

Hillevax Inc

0%

$0

As of today:Mar 24, 10:06:11 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is HLVX?

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

HLVX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	23	29	27	16	5	1
Research & Development	28	78	106	48	47	0
Operating Expenses	51	107	133	65	53	1
Other Non Operating Income (Expenses)	3	4	2	-95	-46	0
Pretax Income	-71	-147	-124	-159	-102	-2
Income Tax Expense	--	--	--	--	--	--
Net Income	-71	-147	-124	-159	-102	-2
Net Income Growth	-54%	19%	-22%	56%	5,000%	--
Shares Outstanding (Diluted)	50.11	49	41	27.15	31.66	31.66
Shares Change (YoY)	2%	20%	51%	-14%	0%	0%
EPS (Diluted)	-1.42	-3	-3.04	-5.89	-3.23	-0.07
EPS Growth	-55%	-1%	-48%	82%	4,514%	250%
Free Cash Flow	-59	-109	-98	-66	-7	-1
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-49	-104	-131	-65	-53	-1
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	2	3	2	0	0	0
EBIT	-51	-107	-133	-65	-53	-1
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	--

Follow-Up Questions

What are Hillevax Inc's key financial statements?



According to the latest financial statement (Form-10K), Hillevax Inc has a total asset of $193, Net loss of $-147

What are the key financial ratios for HLVX?



Hillevax Inc's Current ratio is 5.07, has a Net margin is 0, sales per share of $0.

How is Hillevax Inc's revenue broken down by segment or geography?



Hillevax Inc largest revenue segment is Electricity, at a revenue of 12,018,000,000 in the most earnings release.For geography, Hong Kong is the primary market for Hillevax Inc, at a revenue of 12,057,000,000.

Is Hillevax Inc profitable?



no, according to the latest financial statements, Hillevax Inc has a net loss of $-147

Does Hillevax Inc have any liabilities?



yes, Hillevax Inc has liability of 38

How many outstanding shares for Hillevax Inc?



Hillevax Inc has a total outstanding shares of 50

Hillevax Inc (HLVX) Financial

HLVX Stock Price Chart